Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (53 quarters reported)
$3.38B in Q2 2013 → $143M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Contineum Therapeutics | 8.3% | Unchanged | 727,587 | $11.9M |
| Shoulder Innovations | 6.1% | Unchanged | 430,407 | $8.73M |
| EL Eli Lilly & Co | 5.3% | Unchanged | 6,354 | $7.62M |
| UG Unitedhealth Grp Inc | 3.8% | Trimmed 12% | 13,235 | $5.5M |
| Johnson & Johnson | 3.2% | Unchanged | 18,218 | $4.63M |
| Oruka Therapeutics Inc | 2.8% | New | 41,987 | $4M |
| Biontech Se | 2.7% | Added 89% | 41,869 | $3.9M |
| Definium Therapeutics Inc | 2.6% | New | 78,310 | $3.68M |
| Dexcom Inc | 2.4% | Added 118% | 50,756 | $3.42M |
| Arcus Biosciences | 2.4% | Added 146% | 110,870 | $3.42M |
| Amgen Inc | 2.3% | Unchanged | 9,210 | $3.34M |
| Summit Therapeutics | 2.2% | Added 216% | 220,180 | $3.21M |
| Irhythm Holdings Inc | 2.2% | New | 26,070 | $3.1M |
| Abbvie Inc | 2.1% | Unchanged | 12,200 | $3.07M |
| Merck & Co Inc | 1.9% | Unchanged | 21,480 | $2.77M |
| Arrivent Biopharma | 1.9% | Added 163% | 79,043 | $2.75M |
| VP Vertex Pharma | 1.9% | Trimmed 22% | 5,432 | $2.7M |
| Argenx Se | 1.8% | Trimmed 21% | 2,831 | $2.63M |
| Gilead Sciences Inc | 1.8% | Trimmed 25% | 20,620 | $2.61M |
| Insmed Inc | 1.7% | Added 18% | 23,216 | $2.48M |
| Tectonic Therapeutic | 1.7% | Added 273% | 71,009 | $2.44M |
| IS Intuitive Surgic Inc | 1.6% | Added 11% | 5,850 | $2.33M |
| IN Immatics Nv | 1.6% | Added 237% | 224,928 | $2.28M |
| Stryker Corp | 1.6% | Added 21% | 7,129 | $2.25M |
| Avalo Therapeutics Inc | 1.5% | New | 119,923 | $2.22M |
| Crescent Biopharma Inc. | 1.5% | New | 121,300 | $2.18M |
| Roivant Sciences Ltd | 1.5% | Added 88% | 61,100 | $2.16M |
| Iqvia Holdings Inc | 1.5% | Added 31% | 10,848 | $2.1M |
| Pulse Biosciences Inc | 1.3% | New | 67,895 | $1.88M |
| Danaher Corp | 1.3% | Unchanged | 9,597 | $1.83M |
| Thermo Fisher Scientific | 1.2% | Unchanged | 3,508 | $1.76M |
| AL Abbott Labs | 1.1% | Trimmed 29% | 18,080 | $1.64M |
| AH Alphatec Hldgs Inc | 1.1% | New | 185,900 | $1.61M |
| Boston Scientific | 1.1% | Added 4.5% | 36,330 | $1.55M |
| Transmedics Group Inc | 1.0% | New | 21,950 | $1.46M |
| Cytokinetics Inc | 1.0% | Added 124% | 16,330 | $1.39M |
| RP Regeneron Pharmctcls | 0.9% | Trimmed 26% | 2,169 | $1.35M |
| Cvs Health Corp | 0.9% | New | 13,000 | $1.34M |
| Edwards Lifesciences | 0.9% | Trimmed 14% | 14,826 | $1.34M |
| Trevi Therapeutics | 0.9% | Trimmed 12% | 65,596 | $1.22M |
| Bristol Myers Squibb | 0.9% | Unchanged | 21,150 | $1.22M |
| Vera Therapeutics | 0.8% | Unchanged | 25,573 | $1.1M |
| Cogent Biosciences | 0.7% | Added 21% | 26,740 | $1.03M |
| Medtronic PLC | 0.6% | Unchanged | 11,100 | $876K |
| Tarsus Pharmaceuticals | 0.6% | Added 18% | 13,285 | $836K |
| Kura Oncology Inc | 0.5% | Unchanged | 71,480 | $784K |
| CD Centene Corp Del | 0.5% | New | 12,000 | $770K |
| United Therapeutics | 0.5% | Trimmed 20% | 1,370 | $742K |
| Hinge Health Inc | 0.5% | Trimmed 29% | 8,744 | $726K |
| Nektar Therapeutics | 0.5% | Trimmed 6.8% | 10,111 | $706K |
| AP Alnylam Pharmacuetcl | 0.5% | Unchanged | 2,310 | $695K |
| Ascendis Pharma A/s | 0.5% | New | 2,570 | $685K |
| Pfizer Inc | 0.5% | Unchanged | 27,500 | $662K |
| Ardelyx Inc | 0.4% | Unchanged | 122,394 | $624K |
| Privia Health Group | 0.4% | Trimmed 11% | 24,136 | $621K |
| Ptc Therapeutics Inc | 0.4% | Added 12% | 7,470 | $609K |
| IP Ionis Pharmaceutical | 0.4% | Unchanged | 7,200 | $571K |
| AT Agomab Therapeutics | 0.4% | Unchanged | 43,500 | $565K |
| BP Biomarin Pharmac | 0.4% | Unchanged | 9,450 | $541K |
| BM Beone Medicines Ltd | 0.4% | Unchanged | 1,870 | $533K |
Showing top 60 of 82 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Evommune Inc | Exited | −589,005 | −$13.5M | — |
| Oruka Therapeutics Inc | New | +41,987 | +$4M | 2.8% |
| Definium Therapeutics Inc | New | +78,310 | +$3.68M | 2.6% |
| Irhythm Holdings Inc | New | +26,070 | +$3.1M | 2.2% |
| Avalo Therapeutics Inc | New | +119,923 | +$2.22M | 1.5% |
| Summit Therapeutics | Added | +150,565 | +$2.19M | 2.2% |
| Crescent Biopharma Inc. | New | +121,300 | +$2.18M | 1.5% |
| Arcus Biosciences | Added | +65,800 | +$2.03M | 2.4% |
| Pulse Biosciences Inc | New | +67,895 | +$1.88M | 1.3% |
| Dexcom Inc | Added | +27,525 | +$1.85M | 2.4% |
Showing the 10 largest of 59 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Amgen Inc | Trimmed | −3,860 | −$1.47M | 2.9% |
| Insmed Inc | Added | +8,486 | +$1.46M | 2.8% |
| Gilead Sciences Inc | Added | +9,605 | +$1.44M | 3.4% |
| Iqvia Holdings Inc | New | +8,307 | +$1.42M | 1.2% |
| Astrazeneca | Exited | −15,232 | −$1.4M | — |
| Bristol Myers Squibb | New | +21,150 | +$1.28M | 1.1% |
| Abbvie Inc | Trimmed | −4,600 | −$1M | 2.2% |
| Medtronic PLC | New | +11,100 | +$962K | 0.8% |
| Contineum Therapeutics | Trimmed | −73,200 | −$956K | 7.9% |
| Shoulder Innovations | Trimmed | −62,028 | −$901K | 5.2% |
Showing the 10 largest of 82 changes.
quarter ended December 31, 2025 · filed February 09, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Structure Therapeutics | Trimmed | −198,000 | −$13.8M | 1.3% |
| Evommune Inc | New | +589,005 | +$10.1M | 8.1% |
| Ventyx Biosciences | Trimmed | −1,010,322 | −$9.12M | 0.7% |
| Arcus Biosciences | Trimmed | −311,125 | −$7.41M | 1.1% |
| Anaptysbio Inc | Exited | −194,485 | −$5.96M | — |
| IN Immatics Nv | Trimmed | −497,479 | −$5.22M | 0.5% |
| Bicara Therapeutics | Exited | −266,495 | −$4.21M | — |
| Solid Biosciences | Exited | −633,052 | −$3.91M | — |
| Kura Oncology | Trimmed | −341,762 | −$3.55M | 0.5% |
| Mbx Biosciences Inc | Exited | −194,898 | −$3.41M | — |
Showing the 10 largest of 84 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Lenz Therapeutics | Exited | −977,245 | −$28.6M | — |
| Mineralys Therapeutics | Trimmed | −348,530 | −$13.2M | 0.8% |
| Shoulder Innovations | New | +430,282 | +$5.4M | 3.3% |
| Structure Therapeutics | Added | +170,503 | +$4.77M | 3.8% |
| Rapport Therapeutics | Trimmed | −136,380 | −$4.05M | 0.8% |
| SS SPDR Series Trust | New | +34,000 | +$3.41M | 2.1% |
| Anaptysbio Inc | Added | +110,585 | +$3.39M | 3.7% |
| PT Palvella Therapeutic | Trimmed | −46,500 | −$2.92M | 1.9% |
| Replimune Group Inc | Exited | −231,650 | −$2.15M | — |
| IN Immatics Nv | Added | +228,224 | +$1.94M | 2.9% |
Showing the 10 largest of 77 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Mbx Biosciences Inc | New | +191,825 | +$2.19M | 1.4% |
| PT Palvella Therapeutic | New | +95,615 | +$2.16M | 1.4% |
| Replimune Group Inc | New | +231,650 | +$2.15M | 1.4% |
| OP Oric Pharmaceutica | Added | +211,485 | +$2.15M | 1.6% |
| Medtronic PLC | Exited | −23,850 | −$2.14M | — |
| Solid Biosciences | New | +421,580 | +$2.05M | 1.4% |
| Rapport Therapeutics | New | +179,860 | +$2.05M | 1.4% |
| Zenas Biopharma Inc | New | +210,625 | +$2.04M | 1.3% |
| Ventyx Biosciences | New | +931,620 | +$1.99M | 1.3% |
| Tectonic Therapeutic | New | +98,970 | +$1.97M | 1.3% |
Showing the 10 largest of 88 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| EL Eli Lilly & Co | Trimmed | −3,130 | −$2.59M | 6.1% |
| Gilead Sciences Inc | Trimmed | −19,290 | −$2.16M | 2.8% |
| Bristol-myers Squibb Co | Trimmed | −24,500 | −$1.49M | 0.9% |
| Sarepta Therapeutics | Exited | −11,020 | −$1.34M | — |
| Tenet Healthcare Corp | New | +9,000 | +$1.21M | 0.9% |
| Health Catalyst Inc | Exited | −160,000 | −$1.13M | — |
| Intuitive Surgical Inc | Added | +2,200 | +$1.09M | 2.0% |
| Dexcom Inc | New | +15,000 | +$1.02M | 0.8% |
| Privia Health Group | Exited | −52,000 | −$1.02M | — |
| Radnet Inc | New | +20,000 | +$994K | 0.8% |
Showing the 10 largest of 96 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Iqvia Holdings Inc | Exited | −7,600 | −$1.8M | — |
| ZB Zimmer Biomet Hlds | Exited | −13,500 | −$1.46M | — |
| Uniqure N.v. | Trimmed | −81,500 | −$1.44M | 0.8% |
| Amgen Inc | Added | +5,460 | +$1.42M | 2.2% |
| EL Edwards Lifescience | Trimmed | −18,000 | −$1.33M | 0.4% |
| Icon PLC | Exited | −4,608 | −$1.32M | — |
| Option Care Health | Exited | −40,000 | −$1.25M | — |
| EL Eli Lilly & Co | Added | +1,550 | +$1.2M | 6.5% |
| Health Catalyst Inc | New | +160,000 | +$1.13M | 0.8% |
| Evolent Health Inc | Exited | −39,000 | −$1.1M | — |
Showing the 10 largest of 93 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| LE Lilly Eli & Co | Trimmed | −12,419 | −$11M | 5.8% |
| UG Unitedhealth Grp Inc | Trimmed | −13,550 | −$7.92M | 4.5% |
| Merck & Co Inc | Trimmed | −62,500 | −$7.1M | 1.6% |
| Abbvie Inc | Trimmed | −29,150 | −$5.76M | 1.8% |
| AL Abbott Labs | Trimmed | −46,850 | −$5.34M | 1.3% |
| Johnson & Johnson | Trimmed | −30,950 | −$5.02M | 2.5% |
| Danaher Corp | Trimmed | −12,950 | −$3.6M | 0.8% |
| TF Thermo Fisher Sci | Trimmed | −5,265 | −$3.26M | 1.9% |
| Boston Scientific | Trimmed | −38,450 | −$3.22M | 1.6% |
| RP Regeneron Pharmctcls | Trimmed | −2,640 | −$2.78M | 2.1% |
Showing the 10 largest of 102 changes.
Loading...
